BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.

BeiGene has decided to stop the development ... advanced PD-L1-positive non-small cell lung cancer (NSCLC). "We evaluate our clinical programmes to focus our resources on the most promising ...

In advanced NSCLC after chemotherapy progression, plasma-detected SGVs are common, and associated with inferior OS. Plasma SGV status should be considered as a stratification factor in future trials.

Health policy is crucial for advancing clinical research and ensuring accessibility and funding for novel therapies.

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm ... handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million ...

January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene ... bladder cancer (NMIBC) and non-small cell lung cancer ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Previous estimates had put this risk closer to ... Rates of Breast and Colorectal Cancer Screening Nearly Four-Fold Higher Than Lung Cancer Screening Among Those Eligible Apr. 2, 2025 — Lung ...